Revu Baby Nalanda

Quantitative Determination of the PARP Inhibitor Olaparib (AZD 2281) in Rat Plasma using LC-MS/MS: Application to Pharmacokinetic Studies

Revu Baby Nalanda, Atla Srinivasa Rao, S. Kapileswar & B. Srivani · Journal of Pharmaceutical Research International · 2022

Purpose: Olaparib, a highly selective PARP inhibitor in advanced treatment of ovarian cancer. The method describes a simple, rapid, sensitive, specific LC-ESI-MS/MS assay for the simultaneous detection and accurate measurement of olaparib in rat plasma using telmisartan as an int...

Open access Research Article 10.9734/jpri/2022/v34i39A36232

Stability-indicating Reverse Phase-HPLC Method Development and Method Validation for Quantitative Determination of Degradation Products in Favipiravir API and Drug Product

Varada Soujanya & Revu Baby Nalanda · International Journal of TROPICAL DISEASE & Health · 2024

Introduction: Favipiravir is an antiviral medication shown to be broad spectrum activity against RNA viruses, and potentially treating the COVID-19. Methodology: In this study, the HPLC method for the quantification of degradation impurities (Favipiravir Acid Impurities) were dev...

Open access Research Article 10.9734/ijtdh/2024/v45i71557